中晚期卵巢癌综合治疗的临床疗效观察

Observation of the clinical effects of comprehensive treatment of middle and late ovarian cancer

目的观察、分析中晚期卵巢癌综合治疗的临床疗效。方法选取徐州医科大学附属医院妇科中晚期卵巢癌患者60例，行肿瘤细胞减灭术联合化疗的综合治疗，分析其临床疗效。结果综合治疗后，Ⅱ期卵巢癌患者的5年生存率为50．00％，Ⅲ期卵巢癌患者为47．50％，2组的差异无统计学意义（P〉0．05）；经肿瘤细胞减灭术后无残留病灶患者的5年生存率为57．89％，而残留病灶在1cm及以下的患者为31．82％，2组的差异有统计学意义（P〈0．05）；化疗8个疗程的中晚期卵巢癌患者的5年生存率为61．54％，而化疗疗程不满8个的中晚期卵巢癌患者为33．33％，2组的差异有统计学意义（P〈0．05）。结论综合治疗的疗效与卵巢癌的临床分期无明显关联性；肿瘤细胞减灭术后病灶的残留情况对疗效有显著影响；化疗达8个疗程，则患者的5年生存率增高。

Objective To observe and analyze the clinical efficacy of comprehensive treatment of middle and late o- varian cancer. Methods A total of 60 middle and late ovarian cancer patients in our department were selected to under- go comprehensive treatment including tumor reductive surgery and chemotherapy before efficacy analysis. Results After comprehensive treatment, the 5 -year survival rate was 50.00% for ovarian cancer patients at phase Ⅱ , and 47.50% for those at phase m, without statistical difference （ P 〉 0.05 ）. After tumor reductive surgery, the 5 - year survival rate was 57.89% for patients without residual lesions, which was remarkably different from 31.82% for those with ~〈 1 em residual lesions （ P 〈 0.05 ）. Furthermore, the 5 - year survival rate was 61.54% for middle and late ovarian cancer pa- tients after 8 treatment durations of chemotherapy, which was remarkably different from 33.33 % for those receiving chem- otherapy less than 8 treatment durations （ P 〈 0.05 ）. Conclusions There is no significant relationship between the effi- cacy of comprehensive treatment and the clinical stage of ovarian cancer. The residual lesions after tumor reductive sur- gery can greatly affect efficacy. Patients show a high 5 - year survival rate after 8 treatment durations of chemotherapy.